申请人:TANABE SEIYAKU CO., LTD.
公开号:EP0381335A1
公开(公告)日:1990-08-08
There are disclosed an antiviral agent which comprises a nucleoside of the formula:
wherein B is a thymin-1-yl group, a cytosin-1-yl group, an adenin-9-yl group or a guanin-9-yl group;
and R¹ is amino group when B being a thymin-1-yl group, a cytosin-1-yl group, an adenin-9-yl group or a guanin-9-yl group, -NHCHO when B being a thymin-1-yl group or an adenin-9-yl group, -N=CH₂ when B being a thymin-1-yl group, or -N=C(CH₃)₂ when B being a thymin-1-yl group or an adenin-9-yl group,
or a pharmaceutically acceptable salt thereof as an active therapeutic substance, and a pharmaceutical composition which comprises the nucleoside as mentioned above and a pharmaceutically.acceptable carrier, and a novel nucleoside used therefor.
本发明揭示了一种抗病毒剂,该剂包括以下式子中的核苷:其中B是胸腺嘧啶-1-基基团、胞嘧啶-1-基基团、腺嘌呤-9-基基团或鸟嘌呤-9-基基团;而R¹是氨基基团,当B为胸腺嘧啶-1-基基团、胞嘧啶-1-基基团、腺嘌呤-9-基基团或鸟嘌呤-9-基基团时;是-NHCHO,当B为胸腺嘧啶-1-基基团或腺嘌呤-9-基基团时;是-N=CH₂,当B为胸腺嘧啶-1-基基团时;或是-N=C(CH₃)₂,当B为胸腺嘧啶-1-基基团或腺嘌呤-9-基基团时。该核苷及其药物组成物是一种有效的治疗活性物质,可以与药学上可接受的载体一起使用。同时本发明还揭示了一种新的核苷。